Your browser doesn't support javascript.
Hydroxychloroquine pre-exposure prophylaxis provides no protection against COVID-19 among health care workers: a cross-sectional study in a tertiary care hospital in North India.
Juneja, Shivani; Rana, Proteesh; Chawla, Parvinder; Katoch, Rekha; Singh, Kulvir; Rana, Shobha; Mittal, Tamanna; Kaur, Bhavnish; Kaur, Simranjot.
  • Juneja S; Department of Clinical Pharmacology, Fortis Hospital Mohali, Mohali, India.
  • Rana P; Department of Pharmacology, University College of Medical Sciences, Delhi, India.
  • Chawla P; Fortis Hospital Mohali, Mohali, Punjab, India.
  • Katoch R; Fortis Hospital Mohali, Mohali, Punjab, India.
  • Singh K; Fortis Hospital Mohali, Mohali, Punjab, India.
  • Rana S; Fortis Hospital Mohali, Mohali, Punjab, India.
  • Mittal T; Fortis Hospital Mohali, Mohali, Punjab, India.
  • Kaur B; Fortis Hospital Mohali, Mohali, Punjab, India.
  • Kaur S; Fortis Hospital Mohali, Mohali, Punjab, India.
J Basic Clin Physiol Pharmacol ; 33(1): 103-107, 2022 Jan 07.
Article in English | MEDLINE | ID: covidwho-1613394
ABSTRACT

OBJECTIVES:

The use of Hydroxychloroquine (HCQ) prophylaxis has been recommended by the National task force constituted by the Indian Council of Medical Research (ICMR) for the prevention of corona virus disease 2019 (COVID-19) among healthcare workers (HCWs). However, this recommendation was based essentially on the preclinical data and limited clinical experience. The aim of this study was to evaluate the efficacy and safety of HCQ as a pre-exposure prophylaxis for COVID-19 infection among Indian HCWs.

METHODS:

A cross-sectional study was conducted among HCWs of a tertiary care hospital in north India. The HCQ prophylaxis was initiated among 996 HCWs and they were followed up to 8 weeks for conversion to COVID-19 positive status and any adverse drug reaction (ADR).

RESULTS:

About 10.3% of the study participants were tested positive for COVID-19 which was comparable to the positivity rate among HCWs not taking HCQ prophylaxis (9.7%).

CONCLUSIONS:

HCQ was well tolerated at a weekly dose of 400 mg for 8 weeks but provided no additional benefit in prevention of COVID-19 among HCWs.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pre-Exposure Prophylaxis / COVID-19 / COVID-19 Drug Treatment / Hydroxychloroquine Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Country/Region as subject: Asia Language: English Journal: J Basic Clin Physiol Pharmacol Journal subject: Pharmacology / Physiology Year: 2022 Document Type: Article Affiliation country: Jbcpp-2021-0221

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pre-Exposure Prophylaxis / COVID-19 / COVID-19 Drug Treatment / Hydroxychloroquine Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Country/Region as subject: Asia Language: English Journal: J Basic Clin Physiol Pharmacol Journal subject: Pharmacology / Physiology Year: 2022 Document Type: Article Affiliation country: Jbcpp-2021-0221